Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmablast | 3 studies | 40% ± 15% |
Insufficient scRNA-seq data for expression of APOBEC3B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 77% | 226.69 | 1399 / 1809 | 89% | 11.90 | 420 / 472 |
lung | 81% | 70.44 | 470 / 578 | 80% | 17.24 | 920 / 1155 |
bladder | 71% | 27.48 | 15 / 21 | 86% | 18.08 | 431 / 504 |
stomach | 73% | 80.24 | 261 / 359 | 82% | 10.56 | 235 / 286 |
pancreas | 86% | 79.95 | 282 / 328 | 69% | 5.89 | 122 / 178 |
intestine | 63% | 126.55 | 612 / 966 | 87% | 10.25 | 458 / 527 |
esophagus | 47% | 43.35 | 673 / 1445 | 91% | 15.62 | 166 / 183 |
uterus | 51% | 18.45 | 87 / 170 | 86% | 27.15 | 394 / 459 |
breast | 53% | 27.13 | 243 / 459 | 81% | 13.24 | 909 / 1118 |
ovary | 53% | 21.52 | 95 / 180 | 80% | 11.24 | 342 / 430 |
thymus | 91% | 60.33 | 594 / 653 | 32% | 1.90 | 191 / 605 |
kidney | 66% | 62.87 | 59 / 89 | 34% | 2.11 | 308 / 901 |
spleen | 97% | 260.69 | 233 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 71% | 50.45 | 183 / 258 | 26% | 4.20 | 59 / 230 |
tonsil | 0% | 0 | 0 / 0 | 96% | 54.91 | 43 / 45 |
peripheral blood | 94% | 579.82 | 876 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 72% | 19.24 | 21 / 29 |
liver | 20% | 14.23 | 45 / 226 | 40% | 3.71 | 164 / 406 |
adipose | 49% | 26.57 | 590 / 1204 | 0% | 0 | 0 / 0 |
heart | 48% | 18.05 | 414 / 861 | 0% | 0 | 0 / 0 |
prostate | 36% | 13.78 | 88 / 245 | 12% | 0.54 | 58 / 502 |
brain | 4% | 1.34 | 103 / 2642 | 25% | 1.64 | 174 / 705 |
eye | 0% | 0 | 0 / 0 | 23% | 1.03 | 18 / 80 |
blood vessel | 22% | 9.92 | 296 / 1335 | 0% | 0 | 0 / 0 |
muscle | 3% | 0.57 | 21 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0010526 | Biological process | retrotransposon silencing |
GO_0051607 | Biological process | defense response to virus |
GO_0045869 | Biological process | negative regulation of single stranded viral RNA replication via double stranded DNA intermediate |
GO_0016554 | Biological process | cytidine to uridine editing |
GO_0044355 | Biological process | clearance of foreign intracellular DNA |
GO_0070383 | Biological process | DNA cytosine deamination |
GO_0009972 | Biological process | cytidine deamination |
GO_0045087 | Biological process | innate immune response |
GO_0000932 | Cellular component | P-body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004126 | Molecular function | cytidine deaminase activity |
GO_0003723 | Molecular function | RNA binding |
Gene name | APOBEC3B |
Protein name | Apolipoprotein B mRNA editing enzyme catalytic subunit 3B Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B (Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B, isoform CRA_c) DNA dC->dU-editing enzyme APOBEC-3B (A3B) (EC 3.5.4.38) (Phorbolin-1-related protein) (Phorbolin-2/3) |
Synonyms | hCG_1735023 |
Description | FUNCTION: DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA. Exhibits antiviral activity against simian immunodeficiency virus (SIV), hepatitis B virus (HBV) and human T-cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility of LTR and non-LTR retrotransposons. . |
Accessions | Q9UH17 W0HJ78 ENST00000407298.7 [Q9UH17-3] ENST00000333467.4 [Q9UH17-1] ENST00000402182.7 B0QYD3 ENST00000335760.9 [Q9UH17-2] |